An observational study in Multiple Myeloma, sponsored by Hospices Civils de Lyon. Completed at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-06.
Sponsored by Hospices Civils de Lyon · Observational
Three methods including flow cytometry, next generation sequencing and determination of circulating tumor cells will be performed at different time points in patients with previously undiagnosed multiple myeloma in order to determine the most sensitive method to detect residual disease
3,632 studies on the registry are indexed under Multiple Myeloma; 745 are open to participants now.
This study's enrollment of 48 is below the median of 140 across 468 observational studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Hospices Civils de Lyon is the lead sponsor of 1,826 studies on the registry; 439 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study will focus on adult patients with multiple myeloma and who will receive a treatment with high-dose melphalan and autologous bone marrow transplantation
Exclusion Criteria:
blood samples and bone marrow aspirates will be collected in patients at different time point
Biological: blood samples and bone marrow aspirates will be collected
Serial analysis will be performed at different time point in order to evaluate the presence or absence of residual disease after different treatment steps (before treatment, after induction, after intensification, after consolidation)
Quantification of residual disease
study the sensitivity of the method of quantification of circulating tumor cells compared to 2 others methods of detection
Time frame: Residual disease is assessed up to 18 months after inclusion
kinetic of variation of the residual tumor cells detected by flow cytometry method
% positive cells in bone marrow sample
Time frame: 18 months
kinetic of variation of the residual tumor cells detected by new generation sequencing method
% positive in bone marrow sample
Time frame: 18 months
kinetic of variation of the circulating tumor cells
number of cells / mL of blood
Time frame: 18 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospices Civils de Lyon